Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. August 2008 15:00 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity to Present At Upcoming Conferences

CAMBRIDGE, Mass., Aug. 28, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will...
04. August 2008 16:00 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Highlights Clinical Advances in Its Portfolio of Anti-Chaperone Agents and Announces Second Quarter Financial Results

CAMBRIDGE, Mass., Aug. 4, 2008 (PRIME NEWSWIRE) -- Phase 1 Trial of Oral IPI-493 Enhances Industry-Leading Program Targeting Hsp90 Inhibition Potential First-in-Class...
30. Juli 2008 09:42 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Initiates Clinical Development of IPI-493, Its Oral Anti-Chaperone Agent, in Patients With Advanced Solid Tumors

CAMBRIDGE, Mass., July 30, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has initiated a Phase 1 clinical trial of IPI-493, its oral anti-chaperone...
28. Juli 2008 08:43 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Announces Conference Call Discussing R&D Progress and Second Quarter 2008 Results

CAMBRIDGE, Mass., July 28, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management...
22. Juli 2008 12:43 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Announces the Addition of Two New Board Members and Leadership Promotions

CAMBRIDGE, Mass., July 22, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the appointment of two...
14. Juli 2008 17:13 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Provides Update On Phase 2 Signal-Finding Clinical Study of IPI-504 in Advanced Prostate Cancer

CAMBRIDGE, Ma., July 14, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has decided to discontinue further enrollment in its Phase 2 single agent,...
09. Juli 2008 08:30 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals Named as One of the Best Places to Work

CAMBRIDGE, Mass., July 9, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has been named one...
06. Juni 2008 09:03 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity to Present At Upcoming Conferences

CAMBRIDGE, Mass., June 6, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will...
31. Mai 2008 09:19 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Announces Clinical Data Confirming Activity and Safety of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Refractory GIST

Disease Control Rate and Partial Response Further Validate Potential for Anti-Chaperone Therapy in GIST Phase 3 Registration Trial of Potential First-in-Class Hsp90...
16. Mai 2008 08:27 ET | Quelle: Infinity Pharmaceuticals, Inc.

Infinity Announces Oral Presentation of Results From Clinical Trial of IPI-504 in Patients With GIST At ASCO Annual Meeting

CAMBRIDGE, Mass., May 16, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that updated results from...

Vorherige Seite